LIMITED TARIFF BENEFIT DISCLOSURE STATEMENT

Provide a signed hard copy to the Clerk of the Senate Committee on Finance located at 219 Dirksen SOB and a PDF version sent via email to mtb2009@finance-dem.senate.gov not later than five business days after the date of introduction of the bill. *Please be aware that this form will be made available to the public, media, and any other interested parties.*

Part I. This form is being submitted for S. 1967, which I introduced in the Senate on October 28, 2009. If the bill referenced above is a modification of a previously introduced bill to reflect technical changes, please indicate the previous bill number here: S. _____.

Part II. Please indicate the type of disclosure below: (Please check one only)

☒ The bill referenced in Part I is reasonably anticipated to benefit 10 or fewer individuals or entities, and as such constitutes a Limited Tariff Benefit. (Complete Part III)

☐ The bill referenced in Part I is reasonably anticipated to benefit more than 10 individuals or entities, and as such does not constitute a Limited Tariff Benefit.

Part III. Provide the information below in subparts A, B, and C if the bill referenced above is a Limited Tariff Benefit.

A. Anticipated Beneficiaries:

Syngenta Seeds, Inc.

600 North Armstrong Place

Boise, Idaho 83704

B. Purpose of the Limited Tariff Benefit:

This bill would temporarily eliminate the general rate of duty on formulations of Thiamethoxam, Difenoconazole, Fludioxinil, and Mefenoxam.

C. Financial Benefit Certification

☒ I hereby certify that neither I nor my immediate family has a financial interest in the above described limited tariff benefit.

Mike Crapo

(Member Signature)

October 29, 2009

Date

United States Senator Mike Crapo

(Print Member name)